Navegando por Assunto "Rivaroxaban"

Agora exibindo 1 - 1 de 1

Acesso aberto (Open Access)
Perfil molecular em genes cyp3a4 e cyp2j2: um caminho para a farmacogenética do Rivaroxaban em uma população do Norte do Brasil
(Universidade Federal do Pará, 2014-01-23) TOSCANO, Paulo Martins; SANTOS, Ney Pereira Carneiro dos; http://lattes.cnpq.br/1290427033107137
In recent years, new anticoagulants have been developed with the purpose of minimizing the difficulties encountered in the clinical management of conventional dru- gs, but there are no published data on its pharmacogenetics. Considering the hypothe- sis that polymorphisms related to its metabolism may be the source of genetic variability, this study aims to make inferences on molecular epidemiology of polymorphisms in CyP3a4 (rs2246709) and CyP2j2 (rs890293) genes related to the metabolism of Rivaroxaban, a new direct factor Xa inhibitor. 136 samples from healthy individuals in a population of northern Brazil with a high degree of inter-ethnic mix, so as to guarantee that the pharmacogenetic goal was achieved, have been subjected to a parallel analysis of genomic ancestry for the individuals investigated. The results sho- wed significant differences among genotypes for CyP3a4 observed in the study com- pared to all ancestral populations for a polymorphism 99,365,719 a> G ( P < 0.05). The mixed population of northern Brazil, therefore, showed differences in the distribution of genotype frequencies in relation to ancestral groups, forming our population. The same finding was not observed for the CyP2j2 gene polymorphism. It is noteworthy that the polymorphism in the CyP3a4 gene in the investigated sample is influenced by indivi- dual ethnic European contribution. Considering the high miscegenation featuring local people, and the advancement of Pharmacogenomics in current medicine, such data can contribute to a better understanding of the pharmacogenetics of that new anticoagulant.